BriaCell is hiring! Briacell Therapeutics is expanding our team and looking for passionate, driven individuals to join us in advancing innovative cancer treatments. If you’re ready to make a meaningful impact in biotech and work alongside a dedicated team, we’d love to hear from you. Explore our open roles and take the next step in your career today. bit.ly/478ecPX

Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women's Cancer Program, comments on the encouraging clinical findings from BriaCell's ongoing pivotal Phase 3 study which showed clinically meaningful benefit in heavily pre-treated #metastaticbreastcancer patients. Learn more: bit.ly/4ejBfu3 #ASCO26 $BCTX $BCTXL

Final Bria-IMT Phase 2 data presented at #ASCO26 show 55% >1-year and 27% >2-year survival in heavily pre-treated #metastaticbreastcancer patients treated with the same Bria-IMT formulation as the Phase 3 study. There were no treatment-related discontinuations and no unexpected safety signals. Learn more: bit.ly/4ejBfu3 $BCTX $BCTXL

Saranya Chumsri, MD, principal investigator in the Phase 3 study of Bria-IMT CPI and Professor of Oncology at Mayo Clinic Florida, comments on positive Phase 2 clinical data in heavily pre-treated #metastaticbreastcancer patients presented at #ASCO26. Learn more: bit.ly/4ejBfu3 $BCTX $BCTXL

"We are increasingly optimistic with the early quality of life and biomarker data from our ongoing pivotal Phase 3 Bria-ABC trial demonstrating sustained clinical activity in patients with advanced MBC who did not respond to multiple prior treatments," noted William V. Williams, MD, BriaCell's President & CEO. Learn more: bit.ly/4ejBfu3 $BCTX $BCTXL #ASCO26

BriaCell announced positive clinical data from three poster presentations at the 2026 @ASCO Annual Meeting, taking place May 29–June 2, 2026. The presentations include two posters featuring data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, and one poster highlighting further analyses of Phase 2 data. Find details: bit.ly/4ejBfu3 $BCTX $BCTXL #ASCO26

“Our positive clinical data across six presentations or abstracts at the ASCO 2026 Annual Meeting highlight the progress we are making in our clinical programs,” stated William V. Williams, MD, BriaCell’s President & CEO. To learn more about BriaCell's upcoming participation at #ASCO26, visit: bit.ly/4vogxA7 $BCTX $BCTXL

Saranya Chumsri, M.D., Professor of Oncology at Mayo Clinic Florida and principal investigator in the Phase 3 study of Bria-IMT CPI, comments on the encouraging clinical findings from the Phase 2 study evaluating a whole-cell vaccine in combination with anti-PD-1 therapy for #metastaticbreastcancer patients. bit.ly/4vogxA7 $BCTX $BCTXL #ASCO26

“We are highly encouraged by the sixth consecutive positive recommendation of the DSMB for continuation of BriaCell’s pivotal Phase 3 Bria-ABC study,” stated Dr. William V. Williams, President and Chief Executive Officer of BriaCell. For more information, visit: bit.ly/4dycs6h $BCTX $BCTXL

BriaCell announced that the independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with #metastaticbreastcancer (NCT06072612). Find details: bit.ly/4dycs6h $BCTX $BCTXL

Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women’s Cancer Program, comments on new data from the ongoing pivotal Phase 3 Bria-ABC study evaluating Bria-IMT in #metastaticbreastcancer patients to be presented at #ASCO26. Learn more: bit.ly/4vogxA7 $BCTX $BCTXL

BriaCell announced positive clinical data from three clinical data poster presentations and three publication-only abstracts at the 2026 @ASCO Annual Meeting, taking place May 29 - June 2, 2026. The presentations will include two poster presentations featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, Bria-ABC, and one poster highlighting further analyses of Phase 2 data. For details of the presentations and publish-only abstracts, visit: bit.ly/4vogxA7 $BCTX $BCTXL #ASCO26

Bria-OVA , BriaCell’s next generation personalized #immunotherapy candidate for #ovariancancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity. Learn more from BriaCell's President & CEO, Dr. William V. Williams: bit.ly/4wmxyM6 $BCTX $BCTXL

“The addition of Penn Medicine’s Abramson Cancer Center supports our goal of expanding access to BriaCell’s novel immunotherapy regimen to patients with #metastaticbreastcancer across the greater Philadelphia region,” stated Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. Learn more about BriaCell’s Phase 3 study here: bit.ly/4nK03Qd $BCTX $BCTXL

“We believe Bria-OVA has the potential to provide a differentiated immunotherapeutic approach for #ovariancancer patients with limited treatment options,” stated Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. Learn more: bit.ly/4wmxyM6 $BCTX $BCTXL

BriaCell announced progress in developing Bria-OVA , its next generation, personalized, off-the-shelf, cell-based #immunotherapy for #ovariancancer. Read more: bit.ly/4wmxyM6 $BCTX $BCTXL

“The design of Bria-PROS is intended to support enhanced immune system activation while maintaining a favorable safety profile,"" stated Dr. William V. Williams, BriaCell’s President & CEO. Learn more about BriaCell's completion of clinical supply manufacturing for Bria-PROS , the next generation personalized #immunotherapy candidate for #prostatecancer. bit.ly/4nstOER $BCTX $BCTXL

BriaCell has completed manufacturing clinical supplies of Bria-PROS , its next generation, personalized, off-the-shelf, cell-based #immunotherapy candidate for #prostatecancer. Find details: bit.ly/4nstOER $BCTX $BCTXL

Dr. William V. Williams, BriaCell’s President & CEO, discusses the addition of @PennCancer as a clinical site in BriaCell’s pivotal Phase 3 study. Read more: bit.ly/4nK03Qd $BCTX $BCTXL

BriaCell is pleased to announce the addition of @PennCancer, an internationally recognized cancer center, as a clinical trial site in BriaCell’s ongoing pivotal Phase 3 clinical study (Bria-ABC). Find details: bit.ly/4nK03Qd $BCTX $BCTXL